Selected research
Industry Research
Angina Pectoris Medication Industry Research Report 2026
Market perspective
The global Angina Pectoris Medication market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Angina Pectoris Medication market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Angina Pectoris Medication market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Angina Pectoris Medication market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Angina Pectoris Medication include Sanofi S.A., Novartis AG, Merck & Co., Inc., Eli Lilly and Company, Gilead Sciences, Pfizer Inc., GlaxoSmithKline Plc., Otsuka Pharmaceutical Co., Ltd. and Boehringer Ingelheim International GmbH, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Angina Pectoris Medication market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Angina Pectoris Medication.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Angina Pectoris Medication Market by Company
Sanofi S.A.
Novartis AG
Merck & Co., Inc.
Eli Lilly and Company
Gilead Sciences
Pfizer Inc.
GlaxoSmithKline Plc.
Otsuka Pharmaceutical Co., Ltd.
Boehringer Ingelheim International GmbH
Bayer AG
Amgen Inc.
AstraZeneca
Angina Pectoris Medication Segment by Type
Beta Blockers
Calcium Antagonists
Anticoagulants
Anti-Platelets
Others
Angina Pectoris Medication Segment by Application
Hospitals
Clinics
Others
Angina Pectoris Medication Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angina Pectoris Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Angina Pectoris Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angina Pectoris Medication.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Angina Pectoris Medication companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Beta Blockers
- Calcium Antagonists
- Anticoagulants
- Anti-Platelets
- Others
Applications
- Hospitals
- Clinics
- Others
Companies covered
- Sanofi S.A.
- Novartis AG
- Merck & Co., Inc.
- Eli Lilly and Company
- Gilead Sciences
- Pfizer Inc.
- GlaxoSmithKline Plc.
- Otsuka Pharmaceutical Co., Ltd.
- Boehringer Ingelheim International GmbH
- Bayer AG
- Amgen Inc.
- AstraZeneca
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Angina Pectoris Medication by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Beta Blockers
- 2.2.3 Calcium Antagonists
- 2.2.4 Anticoagulants
- 2.2.5 Anti-Platelets
- 2.2.6 Others
- 2.3 Angina Pectoris Medication by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals
- 2.3.3 Clinics
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Angina Pectoris Medication Breakdown Data by Type
- 3.1 Global Angina Pectoris Medication Historic Market Size by Type (2021-2026)
- 3.2 Global Angina Pectoris Medication Forecasted Market Size by Type (2027-2032)
4 Angina Pectoris Medication Breakdown Data by Application
- 4.1 Global Angina Pectoris Medication Historic Market Size by Application (2021-2026)
- 4.2 Global Angina Pectoris Medication Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Angina Pectoris Medication Market Perspective (2021-2032)
- 5.2 Global Angina Pectoris Medication Growth Trends by Region
- 5.2.1 Global Angina Pectoris Medication Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Angina Pectoris Medication Historic Market Size by Region (2021-2026)
- 5.2.3 Angina Pectoris Medication Forecasted Market Size by Region (2027-2032)
- 5.3 Angina Pectoris Medication Market Dynamics
- 5.3.1 Angina Pectoris Medication Industry Trends
- 5.3.2 Angina Pectoris Medication Market Drivers
- 5.3.3 Angina Pectoris Medication Market Challenges
- 5.3.4 Angina Pectoris Medication Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Angina Pectoris Medication Players by Revenue
- 6.1.1 Global Top Angina Pectoris Medication Players by Revenue (2021-2026)
- 6.1.2 Global Angina Pectoris Medication Revenue Market Share by Players (2021-2026)
- 6.2 Global Angina Pectoris Medication Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Angina Pectoris Medication Head Office and Area Served
- 6.4 Global Angina Pectoris Medication Players, Product Type & Application
- 6.5 Global Angina Pectoris Medication Manufacturers Established Date
- 6.6 Global Angina Pectoris Medication Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Angina Pectoris Medication Market Size (2021-2032)
- 7.2 North America Angina Pectoris Medication Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Angina Pectoris Medication Market Size by Country (2021-2026)
- 7.4 North America Angina Pectoris Medication Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Angina Pectoris Medication Market Size (2021-2032)
- 8.2 Europe Angina Pectoris Medication Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Angina Pectoris Medication Market Size by Country (2021-2026)
- 8.4 Europe Angina Pectoris Medication Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Angina Pectoris Medication Market Size (2021-2032)
- 9.2 Asia-Pacific Angina Pectoris Medication Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Angina Pectoris Medication Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Angina Pectoris Medication Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Angina Pectoris Medication Market Size (2021-2032)
- 10.2 South America Angina Pectoris Medication Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Angina Pectoris Medication Market Size by Country (2021-2026)
- 10.4 South America Angina Pectoris Medication Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Angina Pectoris Medication Market Size (2021-2032)
- 11.2 Middle East & Africa Angina Pectoris Medication Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Angina Pectoris Medication Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Angina Pectoris Medication Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sanofi S.A.
- 12.1.1 Sanofi S.A. Company Information
- 12.1.2 Sanofi S.A. Business Overview
- 12.1.3 Sanofi S.A. Revenue in Angina Pectoris Medication Business (2021-2026)
- 12.1.4 Sanofi S.A. Angina Pectoris Medication Product Portfolio
- 12.1.5 Sanofi S.A. Recent Developments
- 12.2 Novartis AG
- 12.2.1 Novartis AG Company Information
- 12.2.2 Novartis AG Business Overview
- 12.2.3 Novartis AG Revenue in Angina Pectoris Medication Business (2021-2026)
- 12.2.4 Novartis AG Angina Pectoris Medication Product Portfolio
- 12.2.5 Novartis AG Recent Developments
- 12.3 Merck & Co., Inc.
- 12.3.1 Merck & Co., Inc. Company Information
- 12.3.2 Merck & Co., Inc. Business Overview
- 12.3.3 Merck & Co., Inc. Revenue in Angina Pectoris Medication Business (2021-2026)
- 12.3.4 Merck & Co., Inc. Angina Pectoris Medication Product Portfolio
- 12.3.5 Merck & Co., Inc. Recent Developments
- 12.4 Eli Lilly and Company
- 12.4.1 Eli Lilly and Company Company Information
- 12.4.2 Eli Lilly and Company Business Overview
- 12.4.3 Eli Lilly and Company Revenue in Angina Pectoris Medication Business (2021-2026)
- 12.4.4 Eli Lilly and Company Angina Pectoris Medication Product Portfolio
- 12.4.5 Eli Lilly and Company Recent Developments
- 12.5 Gilead Sciences
- 12.5.1 Gilead Sciences Company Information
- 12.5.2 Gilead Sciences Business Overview
- 12.5.3 Gilead Sciences Revenue in Angina Pectoris Medication Business (2021-2026)
- 12.5.4 Gilead Sciences Angina Pectoris Medication Product Portfolio
- 12.5.5 Gilead Sciences Recent Developments
- 12.6 Pfizer Inc.
- 12.6.1 Pfizer Inc. Company Information
- 12.6.2 Pfizer Inc. Business Overview
- 12.6.3 Pfizer Inc. Revenue in Angina Pectoris Medication Business (2021-2026)
- 12.6.4 Pfizer Inc. Angina Pectoris Medication Product Portfolio
- 12.6.5 Pfizer Inc. Recent Developments
- 12.7 GlaxoSmithKline Plc.
- 12.7.1 GlaxoSmithKline Plc. Company Information
- 12.7.2 GlaxoSmithKline Plc. Business Overview
- 12.7.3 GlaxoSmithKline Plc. Revenue in Angina Pectoris Medication Business (2021-2026)
- 12.7.4 GlaxoSmithKline Plc. Angina Pectoris Medication Product Portfolio
- 12.7.5 GlaxoSmithKline Plc. Recent Developments
- 12.8 Otsuka Pharmaceutical Co., Ltd.
- 12.8.1 Otsuka Pharmaceutical Co., Ltd. Company Information
- 12.8.2 Otsuka Pharmaceutical Co., Ltd. Business Overview
- 12.8.3 Otsuka Pharmaceutical Co., Ltd. Revenue in Angina Pectoris Medication Business (2021-2026)
- 12.8.4 Otsuka Pharmaceutical Co., Ltd. Angina Pectoris Medication Product Portfolio
- 12.8.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments
- 12.9 Boehringer Ingelheim International GmbH
- 12.9.1 Boehringer Ingelheim International GmbH Company Information
- 12.9.2 Boehringer Ingelheim International GmbH Business Overview
- 12.9.3 Boehringer Ingelheim International GmbH Revenue in Angina Pectoris Medication Business (2021-2026)
- 12.9.4 Boehringer Ingelheim International GmbH Angina Pectoris Medication Product Portfolio
- 12.9.5 Boehringer Ingelheim International GmbH Recent Developments
- 12.10 Bayer AG
- 12.10.1 Bayer AG Company Information
- 12.10.2 Bayer AG Business Overview
- 12.10.3 Bayer AG Revenue in Angina Pectoris Medication Business (2021-2026)
- 12.10.4 Bayer AG Angina Pectoris Medication Product Portfolio
- 12.10.5 Bayer AG Recent Developments
- 12.11 Amgen Inc.
- 12.11.1 Amgen Inc. Company Information
- 12.11.2 Amgen Inc. Business Overview
- 12.11.3 Amgen Inc. Revenue in Angina Pectoris Medication Business (2021-2026)
- 12.11.4 Amgen Inc. Angina Pectoris Medication Product Portfolio
- 12.11.5 Amgen Inc. Recent Developments
- 12.12 AstraZeneca
- 12.12.1 AstraZeneca Company Information
- 12.12.2 AstraZeneca Business Overview
- 12.12.3 AstraZeneca Revenue in Angina Pectoris Medication Business (2021-2026)
- 12.12.4 AstraZeneca Angina Pectoris Medication Product Portfolio
- 12.12.5 AstraZeneca Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst